代谢功能障碍相关脂肪性肝病有哪些新进展？
What is new in metabolic dysfunction-associated steatotic liver disease?
作者信息
Tan Kathryn Cb
机构信息
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
出版信息
J Diabetes Investig. 2025 Apr;16(4):581-583. doi: 10.1111/jdi.70003. Epub 2025 Feb 1.
Abstract
The change in nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction associated-steatotic liver disease has emphasized the importance of metabolic abnormalities in this liver disorder. New pharmacological therapy has recently become available and resmetirom, a thyroid hormone receptor agonist, has received approval for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis and significant liver fibrosis.
摘要
从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名变化，凸显了代谢异常在这种肝脏疾病中的重要性。最近有了新的药物疗法，甲状腺激素受体激动剂resmetirom已获批用于治疗非肝硬化性代谢功能障碍相关脂肪性肝炎和显著肝纤维化。
相似文献
1
What is new in metabolic dysfunction-associated steatotic liver disease?代谢功能障碍相关脂肪性肝病有哪些新进展？
J Diabetes Investig. 2025 Apr;16(4):581-583. doi: 10.1111/jdi.70003. Epub 2025 Feb 1.
2
Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.肝脏甲状腺激素受体-β信号传导：代谢功能障碍相关脂肪性肝炎治疗的机制与最新进展
Diabetes Obes Metab. 2025 Apr;27(4):1635-1647. doi: 10.1111/dom.16117. Epub 2024 Dec 10.
3
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.选择性甲状腺激素受体-β激动剂 Resmetirom 治疗代谢功能障碍相关脂肪性肝病（MASLD）的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.
4
Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?雷西莫特罗姆，期待已久的治疗代谢功能障碍相关脂肪性肝炎和肝纤维化的首种疗法？
Med. 2024 May 10;5(5):375-376. doi: 10.1016/j.medj.2024.03.013.
5
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎的当前治疗现状
Int J Mol Sci. 2025 Feb 19;26(4):1778. doi: 10.3390/ijms26041778.
6
Clinical Insights on Resmetirom: Clinical Indications, Patient Selection, and Monitoring Response to Therapy.关于瑞美替昂的临床见解：临床适应症、患者选择及治疗反应监测
J Clin Gastroenterol. 2025;59(5):412-419. doi: 10.1097/MCG.0000000000002150. Epub 2025 Feb 13.
7
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.代谢功能障碍相关脂肪性肝病：诊断与管理的近期转折点
Metabolism. 2024 Aug;157:155936. doi: 10.1016/j.metabol.2024.155936. Epub 2024 May 17.
8
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
9
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders.探索胰高血糖素样肽-1激动剂在代谢紊乱中的治疗潜力。
World J Gastroenterol. 2025 Jan 28;31(4):101436. doi: 10.3748/wjg.v31.i4.101436.
10
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).代谢功能障碍相关脂肪性肝炎（MASH）的治疗前景
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
本文引用的文献
1
Hepatokine leukocyte cell-derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction-associated steatotic liver disease in the general population.肝源细胞因子白细胞衍生趋化因子2作为普通人群胰岛素抵抗、肝酶及代谢功能障碍相关脂肪性肝病的生物标志物
J Diabetes Investig. 2025 Feb;16(2):298-308. doi: 10.1111/jdi.14351. Epub 2024 Nov 21.
2
Metabolic dysfunction-associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria - NAGALA study.代谢功能障碍相关脂肪性肝病：相较于传统标准，对2型糖尿病发病的更优预测指标——NAGALA研究
J Diabetes Investig. 2024 Dec;15(12):1788-1796. doi: 10.1111/jdi.14315. Epub 2024 Sep 16.
3
Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high-fat, high-sucrose diet-fed mice.依格列净通过间接机制增强胰高血糖素分泌，并改善高脂肪、高蔗糖饮食喂养的小鼠的脂肪肝。
J Diabetes Investig. 2024 Sep;15(9):1177-1190. doi: 10.1111/jdi.14249. Epub 2024 Jun 14.
4
Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.吡格列酮和伊格列净对 2 型糖尿病代谢功能障碍相关脂肪性肝病的长期影响：一项为期 24 周、随机、活性对照试验的 5 年观察随访：伊格列净在 MASLD 中的作用。
J Diabetes Investig. 2024 Sep;15(9):1220-1230. doi: 10.1111/jdi.14246. Epub 2024 May 22.
5
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
6
Elevated small dense low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with an increased risk of metabolic dysfunction associated fatty liver disease in Chinese patients with type 2 diabetes mellitus.小而密低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值升高与中国 2 型糖尿病患者代谢功能障碍相关脂肪性肝病风险增加相关。
J Diabetes Investig. 2024 May;15(5):634-642. doi: 10.1111/jdi.14148. Epub 2024 Jan 22.
7
Estimated small dense low-density lipoprotein cholesterol and nonalcoholic fatty liver disease in nonobese populations.非肥胖人群中小而密的低密度脂蛋白胆固醇与非酒精性脂肪性肝病。
J Diabetes Investig. 2024 Apr;15(4):491-499. doi: 10.1111/jdi.14133. Epub 2023 Dec 18.
8
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病无创生物标志物的进展
Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115.
9
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.雷美替胺治疗非酒精性脂肪性肝病：一项随机、双盲、安慰剂对照的 3 期临床试验。
Nat Med. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16.
10
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.99%的非酒精性脂肪性肝病患者符合代谢功能障碍相关脂肪性肝病标准，因此其自然病史相同。
J Hepatol. 2024 Feb;80(2):e76-e77. doi: 10.1016/j.jhep.2023.08.026. Epub 2023 Sep 9.
Zotero 插件